# MEDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medx

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.medxtmc.com
- Total disclosed funding: $77M
- Latest round: Series B (Sep 28, 2020)
- Investors on record: 7

## About

Established in 2013 and based in Suzhou, China, MEDx is a translational medicine service platform that provides biomarker discovery, validation, molecular detection and inclusion screening of patients in clinical trials of new drugs, detection method development, etc. As of 2023, this company has more than 200 pharmaceutical customers and more than 200 biomarker discovery and detection methods.

The company focuses on providing one-stop services ranging from biomarker discovery and assay development, to patient molecular testing and enrollment screening for clinical trials of new drugs, as well as companion diagnostic kit development and commercialization.

## Funding rounds

- Series B, Sep 28, 2020, $52M — Qiming Venture Partners, Shanghai Jianyi Private Equity Fund Management, Broad Resources, Shanghai Anjie Medical Equipment, Quan Venture Capital, Tsing Song Capital
- Series A, Jun 30, 2017, $26M — Qiming Venture Partners, New Horizon Capital, Shanghai Anjie Medical Equipment, Quan Venture Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- New Horizon Capital — Series A
- Shanghai Anjie Medical Equipment — Series A, Series B
- Quan Venture Capital — Series A, Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- Broad Resources (https://capitalatlas.ai/funds/broad-resources) — Series B
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series B